Maureen Bamfo-Agyei
Psychiatric/Mental Health · Weldon Spring, MONPI 1932724556
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 386 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,988 and has fallen 82.8% since, to $513 in 2024. Among psychiatric/mental health clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 386 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Sunovion Pharmaceuticals Inc.$984
- Otsuka America Pharmaceutical, Inc.$902
- Teva Pharmaceuticals USA, Inc.$536
- Alkermes, Inc.$476
- Johnson & Johnson$419
- plus $2K from 12 others
What the payments were for
- Food & beverage$6,55999%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 67 | $1,186 |
| Sunovion Pharmaceuticals Inc. | 63 | $984 |
| Otsuka America Pharmaceutical, Inc. | 46 | $902 |
| Teva Pharmaceuticals USA, Inc. | 45 | $536 |
| Alkermes, Inc. | 33 | $476 |
| Johnson & Johnson | 21 | $419 |
| Neurocrine Biosciences, Inc. | 22 | $402 |
| Lundbeck LLC | 24 | $288 |
| Vanda Pharmaceuticals Inc. | 15 | $268 |
| Noven Therapeutics, LLC | 20 | $259 |
| AbbVie | 6 | $201 |
| Axsome Therapeutics, Inc. | 3 | $198 |
| Indivior Inc. | 8 | $133 |
| E.r. Squibb & Sons, L.L.C. | 1 | $126 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $107 |
| Almatica Pharma LLC | 2 | $53 |
| Noven Pharmaceuticals, Inc. | 2 | $45 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,606 in reported general payments places this provider in the 90th percentile of 565 psychiatric/mental health providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 33 | $109,865 |
| Abilify MaintenaAripiprazole | 33 | $96,328 |
| VraylarCariprazine Hcl | 22 | $30,558 |
| Risperdal ConstaRisperidone Microspheres | 18 | $23,537 |
| Aripiprazole | 162 | $10,827 |
| FetzimaLevomilnacipran Hcl | 17 | $8,336 |
| Lurasidone Hcl | 34 | $5,173 |
| Paliperidone ErPaliperidone | 22 | $3,517 |
| Atomoxetine Hcl | 22 | $2,247 |
| Quetiapine Fumarate | 71 | $1,364 |
| Acamprosate Calcium | 12 | $1,213 |
| Naltrexone Hcl | 17 | $1,129 |
| Trazodone Hcl | 221 | $1,067 |
| Buspirone Hcl | 77 | $877 |
| Olanzapine | 62 | $852 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $419 | $133,40251 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $902 | $96,32833 claims |
| AbbVieVraylar, Fetzima | $201 | $38,89439 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $536 | $61321 claims |
| Almatica Pharma LLCSertraline Hcl | $53 | $35881 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 565 psychiatric/mental health providers in Missouri.
Other psychiatric/mental health in Weldon Spring
- Danielle DunyoWeldon Spring$15K
- Amanda KearneyWeldon Spring$12K
- Dianna PharesWeldon Spring$8K
- Christina MitchellWeldon Spring$7K
- Aldijana SacicSaint Louis$510K
- Erin DuvallSpringfield$275K
- Laurel OwensLees Summit$246K
- Julie WaterburySaint Louis$135K
- Emily WoukSpringfield$90K
- Kristerpher BrimberryPoplar Bluff$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.